Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYRO3 | Q06418 | 3/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 8/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 8/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 8/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 7/20 | 0.39 |
| ▸ | CSF1R | P07333 | 1/20 | 0.39 |
| ▸ | ATR | Q13535 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30452950 | 1.00 | TYRO3 (0.41) | TYRO3PIK3CDPIK3CAPIK3CGPIK3CB | |
| SCHEMBL30452487 | 0.92 | TYRO3 (0.42) | TYRO3PIK3CDPIK3CAPIK3CGPIK3CB | |
| SCHEMBL488225 | 0.92 | TYRO3 (0.42) | TYRO3PIK3CDPIK3CAPIK3CGPIK3CB | |
| SCHEMBL30452448 | 0.90 | SGK1 (0.38) | PIK3CDPIK3CAPIK3CGPIK3CBCSF1R | |
| SCHEMBL488075 | 0.90 | SGK1 (0.38) | PIK3CDPIK3CAPIK3CGPIK3CBCSF1R | |
| SCHEMBL487815 | 0.86 | MET (0.40) | JAK2 | |
| SCHEMBL30453026 | 0.86 | MET (0.40) | JAK2 | |
| SCHEMBL488736 | 0.84 | TYRO3 (0.42) | TYRO3PIK3CDPIK3CAPIK3CGPIK3CB | |
| SCHEMBL487930 | 0.84 | MAP4K4 (0.45) | TYRO3PIK3CDPIK3CAPIK3CGPIK3CB | |
| SCHEMBL30454893 | 0.84 | MAP4K4 (0.45) | TYRO3PIK3CDPIK3CAPIK3CGPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4695588-B2 | — | — | 2011-06-08 | — | — | JP | claimed |
| US-8106197-B2 | Aminoheteroaryl compounds as protein kinase inhibitors | PFIZER INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-8106197-B2 | Aminoheteroaryl compounds as protein kinase inhibitors | PFIZER INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-8106197-B2 | Aminoheteroaryl compounds as protein kinase inhibitors | PFIZER INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-7230098-B2 | 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer | SUGEN, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-7230098-B2 | 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer | SUGEN, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-20070072874-A1 | Aminoheteroaryl compounds as protein kinase inhibitors | SUGEN, INC. | 2007-03-29 | — | — | US | disclosed |
| US-20070072874-A1 | Aminoheteroaryl compounds as protein kinase inhibitors | SUGEN, INC. | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072874-A1 | Aminoheteroaryl compounds as protein kinase inhibitors | MET, MAP4K1, MAP4K2 | TYRO3 416/4885PIK3CD 407/4885PIK3CA 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.